MGMT and neoplasm: Importantly, previous research has found that individuals with clinical features including IDH mutation, 1p19q codeletion, and MGMT methylation, were more likely to be in the C5 subtype (31) and possess a better immune microenvironment (32), which decreased leukocyte chemotaxis and infiltrated tumor-related immune cells (33).